REGENERON PHARMACEUTICALS, INC. 8-K

What Happened
On April 29, 2026, Regeneron Pharmaceuticals, Inc. (REGN) announced its financial and operating results for the quarter ended March 31, 2026 via a press release. That press release was furnished to the SEC as Exhibit 99.1 to the Current Report on Form 8-K filed the same day and is incorporated by reference into the filing.

Key Details

• Press release dated April 29, 2026 reporting quarterly results for the period ended March 31, 2026 (furnished as Exhibit 99.1).
• The Form 8-K discloses the results under Item 2.02 (Results of Operations and Financial Condition).
• The filing includes an Inline XBRL cover page interactive data file (Exhibit 104).
• The Form 8-K was signed April 29, 2026 by Joseph J. LaRosa, Executive Vice President, General Counsel and Secretary.

Why It Matters
This filing notifies investors that Regeneron has released its most recent quarterly earnings and operating metrics; those results (revenue, earnings, guidance or operational updates) are material for assessing near-term performance and valuation. Investors should review the April 29 press release (Exhibit 99.1) for specific figures and commentary that could affect the company’s stock, trading activity, and short-term outlook.